![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial
|
|
|
EASL 2023 june 21-24 vienna
![0705231](../images/070523/070523-5/0705231.gif)
![0705232](../images/070523/070523-5/0705232.gif)
![0705233](../images/070523/070523-5/0705233.gif)
![0705234](../images/070523/070523-5/0705234.gif)
![0705235](../images/070523/070523-5/0705235.gif)
![0705236](../images/070523/070523-5/0705236.gif)
![0705237](../images/070523/070523-5/0705237.gif)
![0705238](../images/070523/070523-5/0705238.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|